BioMed is announcing the merger of its two largest medical companies, Biogen and BioMed Inc., in a deal that will create the world’s largest pharmaceutical company.
BioMed will now be known as BioMed BioPharma.
The combined company will be called Biogen Inc., and it will operate in a variety of industries.
The deal will bring together Biogen’s expertise in a range of medical devices, including a portfolio of devices developed and marketed by BioMed.
“BioMed is uniquely positioned to be a leader in a rapidly growing market in the development and commercialization of medical products that use new technology to deliver significant and life-changing benefits,” said Biogen CEO, John W. Bresnahan, in a statement.
The new company will have $1.6 billion in assets under management and will be led by CEO Andrew Koppelman, Biomet President and Chief Technology Officer, and President and CEO of BioMed, Dr. Jeffrey H. Hochstein.
The company will also be led in medical device development by Biogen Biotechs R&D leader, Drs.
Jeffrey W. Johnson, M.D., and James R. Miller, M,D., who will join the board.
Biogen BioPharmaceuticals and Biogen are expected to combine their expertise in the medical device industry.
“Biogen has a proven track record of delivering innovative products and services that benefit patients, their families, and our global partners.
By joining forces, we will continue to build upon this reputation to create a world-class product development, commercialization and manufacturing network for medical devices,” said Hochsteins chief executive officer, Jeff Johnson.
“The combined company has the ability to accelerate the growth of our global medical device and diagnostic device development efforts, with a combined product development capability that will make us a leader on the international stage.”
Biogen will continue its efforts to develop new medical devices to help patients live healthier lives.
In the past, it has worked with leading pharmaceutical companies including Novartis, Pfizer and Merck, as well as with several other large health care companies including Gilead Sciences, AbbVie, and Pfizer, for the development of vaccines, therapeutics and devices.
BiMed BioMed’s mission is to provide products and solutions that will enhance the lives of patients, health care professionals and caregivers.
“By working closely with BioMed and its leadership team, we are confident that our products and technologies will deliver new and meaningful benefits to our customers, our patients and our patients’ families,” Hochstins said.
BioMD Biolog is a specialty pharmaceutical company that specializes in treating the common chronic and infectious diseases.
It was founded in 2000 by Dr. John W Koppel and Dr. Richard M Miller.
BioMedic Biomed is a biotechnology company with a focused on the development, production and commercialisation of novel biological therapeutics for the treatment of a variety a variety, of conditions.
BiMedic BioMed also provides an integrated portfolio of medical device solutions to health care providers and patients worldwide.
The products BiMed sells include, but are not limited to, devices that are used to monitor, monitor and control the heart, brain, pancreas, kidneys, liver, skin and skin disorders, arthritis, diabetes, cancer, chronic fatigue syndrome, epilepsy, HIV/AIDS, multiple sclerosis, Parkinson’s disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, neuropathy, and multiple sclerosis.
BioMeds products include, or include: Therapeutic Goods, Devices, Pharmaceuticals, Devices for Healthcare, Medical Device, Diagnostic Device, Therapeutics, Devices that Treat and Treat Multiple Diseases, Therapies for Multiple Diseases and Therapeuticals for Multiple Disorders.
BioPhar Biolog, Biomedical’s parent company, is headquartered in Palo Alto, California.
BioMTX is a global leader in the delivery of the Biotech-as-a-Service (BAS) product portfolio for pharmaceutical companies.
BiMTX’s portfolio of Biolog and BioMD’s Biolog-branded products includes products developed and patented by BiMed and BioMets, as of January 1, 2019, and approved for the United States market by the U.S. Food and Drug Administration (FDA) and other U.N. regulatory agencies.
BioMedical, the parent company of BioMD, is based in New York City.
For more information on the merger, please visit the company’s press release at: http://bit.ly/2aX4e5z.
For additional information on BioMed News, please go to: http:/www.biomednews.com/news/business/biomed-acquires-michigans-biogen-marijuana-bioscience-company-biomell-news-mercedes-fiat-fcc-michael